A Phase III, Multicentre, Randomised, Double-blind,
Chronic-dosing, Parallel-group, Placebo-controlled Study to
Evaluate the Efficacy and Safety of Two Dose Regimens of
MEDI3506 in Participants with Symptomatic Chronic
Obstructive Pulmonary Disease (COPD) with a History of COPD
Exacerbations (TITANIA)
